Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.

Subjects

Subjects :

Alendronate adverse effects
Alendronate therapeutic use
Bone Density Conservation Agents adverse effects
Bone Density Conservation Agents therapeutic use
Cost-Benefit Analysis
Estrogen Replacement Therapy adverse effects
Female
Humans
Mass Screening economics
Middle Aged
Osteoporosis, Postmenopausal mortality
Raloxifene Hydrochloride adverse effects
Raloxifene Hydrochloride therapeutic use
Selective Estrogen Receptor Modulators adverse effects
Selective Estrogen Receptor Modulators therapeutic use
Venous Thrombosis mortality
Alendronate economics
Bone Density Conservation Agents economics
Decision Support Techniques
Estrogen Replacement Therapy economics
Osteoporosis, Postmenopausal economics
Raloxifene Hydrochloride economics
Selective Estrogen Receptor Modulators economics
Venous Thrombosis chemically induced
Venous Thrombosis economics

Details

Language :

English

ISSN :

0272-989X

Volume :

26

Issue :

6

Database :

MEDLINE

Journal :

Medical decision making : an international journal of the Society for Medical Decision Making

Publication Type :

Academic Journal

Accession number :

17099202

Full Text :

https://doi.org/10.1177/0272989X06295363